ES2378072T3 - Procedimiento para reducir la toxicidad gastrointestinal debida a la administración de tegafur - Google Patents

Procedimiento para reducir la toxicidad gastrointestinal debida a la administración de tegafur Download PDF

Info

Publication number
ES2378072T3
ES2378072T3 ES05738545T ES05738545T ES2378072T3 ES 2378072 T3 ES2378072 T3 ES 2378072T3 ES 05738545 T ES05738545 T ES 05738545T ES 05738545 T ES05738545 T ES 05738545T ES 2378072 T3 ES2378072 T3 ES 2378072T3
Authority
ES
Spain
Prior art keywords
tegafur
composition
administered
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05738545T
Other languages
English (en)
Spanish (es)
Inventor
Takeshi Tahara
Hiroshi Ambe
Jun Kuritani
Naruo Nomura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2378072T3 publication Critical patent/ES2378072T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES05738545T 2004-04-29 2005-04-27 Procedimiento para reducir la toxicidad gastrointestinal debida a la administración de tegafur Expired - Lifetime ES2378072T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56618004P 2004-04-29 2004-04-29
US566180P 2004-04-29
PCT/JP2005/008450 WO2005105086A1 (en) 2004-04-29 2005-04-27 Method for reducing gastrointestinal toxicity due to the administration of tegafur

Publications (1)

Publication Number Publication Date
ES2378072T3 true ES2378072T3 (es) 2012-04-04

Family

ID=35241420

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05738545T Expired - Lifetime ES2378072T3 (es) 2004-04-29 2005-04-27 Procedimiento para reducir la toxicidad gastrointestinal debida a la administración de tegafur

Country Status (16)

Country Link
US (1) US20080166427A1 (https=)
EP (1) EP1750703B1 (https=)
JP (1) JP5376758B2 (https=)
AT (1) ATE540679T1 (https=)
AU (1) AU2005237364B2 (https=)
CY (2) CY1112451T1 (https=)
DK (1) DK1750703T3 (https=)
ES (1) ES2378072T3 (https=)
HR (1) HRP20120293T1 (https=)
ME (1) ME01335B (https=)
PL (1) PL1750703T3 (https=)
PT (1) PT1750703E (https=)
RS (1) RS52217B (https=)
RU (1) RU2348409C2 (https=)
SI (1) SI1750703T1 (https=)
WO (1) WO2005105086A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010131769A1 (en) * 2009-05-13 2010-11-18 Taiho Pharmaceutical Co., Ltd. Treatment of diffuse-type gastric cancers using s-1 and cisplatin
CN102648412A (zh) * 2009-07-17 2012-08-22 美瑞德生物工程公司 5-fu的检测方法
WO2011022174A1 (en) * 2009-08-21 2011-02-24 Myriad Genetics, Inc. Method of processing blood samples containing 5-fu
EP2422784A1 (en) 2010-08-18 2012-02-29 Grindeks, a joint stock company Composition of TEGAFUR, caffeic acid phenethyl ester (CAPE) and either catechin, kaempherol, myricetin or luteolin for potentiating antitumour effect and for treating tumours
EP2422848A1 (en) 2010-08-18 2012-02-29 Grindeks, a joint stock company Composition of tegafur, Indole-3-carbinol and either catechin, kaempherol, myricetin or luteolin for potentiating antitumour effect and for treating tumours
EP2422815A1 (en) 2010-08-18 2012-02-29 Grindeks, a joint stock company Pharmaceutical composition of tegafur and natural flavonoid derivative catechin for potentiating antitumour effect and for treating tumours
US10172839B2 (en) 2014-03-06 2019-01-08 University Of Southern California Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
WO2015134837A2 (en) * 2014-03-06 2015-09-11 University Of Southern California Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
CA2944088C (en) * 2014-03-28 2022-06-21 L-Nutra Inc. Tyrosine kinase inhibitors for use in a method of treating cancer in association with a reduced caloric intake
EP3290038A4 (en) * 2015-04-30 2018-12-26 Taiho Pharmaceutical Co., Ltd. Agent for alleviating adverse reaction to antitumor drug
JP6439761B2 (ja) * 2016-08-09 2018-12-19 トヨタ自動車株式会社 ＮＯｘ吸蔵還元触媒の製造方法
CN106619689B (zh) * 2016-12-30 2018-05-01 陈晓华 一种用于治疗癌症的药物组合物、试剂盒及其应用
US20250186435A1 (en) * 2020-05-19 2025-06-12 Cellix Bio Private Limited Pharmaceutical formulations and their preparations for treatment of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3635946A (en) * 1969-07-22 1972-01-18 Solomon Aronovich Giller N1-(2'-furanidyl)-derivatives of 5-substituted uracils
EP0180188B1 (en) * 1984-10-30 1992-04-15 Otsuka Pharmaceutical Co., Ltd. A composition for increasing the anti-cancer activity of an anti-cancer compound
US5968914A (en) * 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
NL194430C (nl) * 1989-01-05 2002-04-04 Otsuka Pharma Co Ltd Niet-injecteerbaar farmaceutisch preparaat met anti-kankerwerking.
WO1992021345A1 (en) * 1991-05-27 1992-12-10 Taiho Pharmaceutical Co., Ltd. Composition, method and kit for potentiating antitumor activity and for curing tumor
RU2198171C2 (ru) * 1998-10-12 2003-02-10 Леонидов Николай Борисович Новая кристаллическая модификация 5-фтор-1-(тетрагидро-2-фурил)-урацила и комплексные соединения на ее основе, обладающие противоопухолевым действием

Also Published As

Publication number Publication date
ATE540679T1 (de) 2012-01-15
DK1750703T3 (da) 2012-05-07
RS52217B (sr) 2012-10-31
ME01335B (me) 2013-12-20
SI1750703T1 (sl) 2012-02-29
AU2005237364A1 (en) 2005-11-10
EP1750703B1 (en) 2012-01-11
CY2012014I1 (el) 2016-04-13
AU2005237364B2 (en) 2010-07-08
US20080166427A1 (en) 2008-07-10
RU2348409C2 (ru) 2009-03-10
CY1112451T1 (el) 2015-12-09
EP1750703A1 (en) 2007-02-14
PL1750703T3 (pl) 2012-05-31
HRP20120293T1 (hr) 2012-04-30
WO2005105086A1 (en) 2005-11-10
JP2007534634A (ja) 2007-11-29
JP5376758B2 (ja) 2013-12-25
PT1750703E (pt) 2012-02-23
CY2012014I2 (el) 2016-04-13
EP1750703A4 (en) 2008-02-27
RU2006142101A (ru) 2008-06-20

Similar Documents

Publication Publication Date Title
EP1849470B2 (en) Anticancer drug containing alpha, alpha, alpha-trifluorothymidine and thymidine phosphorylase inhibitor
ES2378072T3 (es) Procedimiento para reducir la toxicidad gastrointestinal debida a la administración de tegafur
Chollet et al. Phase II trial with S-1 in chemotherapy-naıve patients with gastric cancer. A trial performed by the EORTC early clinical studies group (ECSG)
US20130184232A1 (en) Methods for administering dpd inhibitors in combination with 5-fu and 5-fu prodrugs
US6503889B2 (en) Composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
US7799783B2 (en) Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
CN104159589A (zh) 肝脏状况的治疗
ES2926934T3 (es) Inhibidores de tirosina quinasa para uso en un método de tratar cáncer en asociación con una ingesta calórica reducida
RU2334517C2 (ru) Средство, потенцирующее противоопухолевый эффект, и противоопухолевое средство
JP2007534634A5 (https=)
ES3026709T3 (en) Cancer treatment using docetaxel by controlling peak plasma levels
Roviello et al. TAS-102 in gastric cancer: Development and perspectives of a new biochemically modulated fluroropyrimidine drug combination
Eng et al. Oral fluoropyrimidine treatment of colorectal cancer
WO2008109349A1 (en) Improved regimen for treating cancer with 5-fluorouracil, 5,10-methylenetetrahydrofolate and capecitabine
Schwartz et al. Raltitrexed (Tomudex™) in combination with 5-fluorouracil for the treatment of patients with advanced colorectal cancer: preliminary results from phase I clinical trials
ES2348996T3 (es) Potenciador de radioterapia.
CN114650816A (zh) 用于治疗胆管癌的包含帕比司他的联合疗法
Choi et al. Phase I trial of neoadjuvant concurrent chemoradiotherapy with S-1 and weekly irinotecan in locally advanced rectal cancer
Fukushima S-1 review from preclinical pharmacology
HK40121791A (zh) 利用mta协作的prmt5抑制剂的癌症治疗
Shirasaka et al. Preclinical and clinical practice of S-1 in Japan
US20140038966A1 (en) Tegafur-containing composition for single daily and alternate-day dosing